Stockscreener 앱 받기
2.00
1.96%
-0.04
시간 외 거래:
1.96
-0.04
-2.00%
전일 마감가:
$2.04
열려 있는:
$2.03
하루 거래량:
135.31K
Relative Volume:
0.05
시가총액:
$9.60M
수익:
-
순이익/손실:
$-11.66M
주가수익비율:
-0.2452
EPS:
-8.156
순현금흐름:
$-11.09M
1주 성능:
+14.29%
1개월 성능:
+1.01%
6개월 성능:
-26.47%
1년 성능:
-70.45%
1일 변동 폭
$1.95
$2.03
1주일 범위
$1.71
$2.08
52주 변동 폭
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
명칭
Phio Pharmaceuticals Corp
전화
(508) 767-3861
주소
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
PHIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.00 | 8.40M | 0 | -11.66M | -11.09M | -8.156 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-05 | 개시 | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp 주식(PHIO)의 최신 뉴스
Best Value Stocks to Buy for May 28th - Zacks Investment Research
New Strong Buy Stocks for May 28th - The Globe and Mail
New Strong Buy Stocks For May 28th - Barchart.com
Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile
Phio Cancer Treatment Shows Breakthrough Results: 44% Complete Response Rate in Latest Clinical Trial Data - Stock Titan
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks
Phio reports positive results in skin cancer trial - Investing.com
Phio reports positive results in skin cancer trial By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals (PHIO) to Release Earnings on Thursday - Defense World
Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts
Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister
Best Momentum Stocks to Buy for April 23rd - TradingView
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com
Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World
Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN
3 Penny Stocks to Watch Now, 4/10/25 - TipRanks
Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled - MSN
Phio advances skin cancer treatment with successful trial By Investing.com - Investing.com South Africa
This Biotech Is Ripping Following Phase 1b Trial Announcement - The Globe and Mail
Crude Oil Down 4%; Neogen Shares Plunge After Q3 ResultsBloom Energy (NYSE:BE), Neogen (NASDAQ:NEOG) - Benzinga
Phio Pharmaceuticals Advances PH-762 Cancer Treatment in Phase 1 - GuruFocus
PHIO Advances PH-762 in Phase 1b Clinical Trial for Skin Cancers - GuruFocus
Is Phio’s Surge Sustainable? - timothysykes.com
Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation - marketscreener.com
Phio advances skin cancer treatment with successful trial - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile
Breakthrough in Skin Cancer Trial: PH-762 Shows 100% Tumor Clearance as Study Advances - Stock Titan
Phio stock hits 52-week low at $0.99 amid sharp annual decline - Investing.com
Phio Pharmaceuticals’ (PHIO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Phio stock hits 52-week low at $0.99 amid sharp annual decline By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 - Investing.com Australia
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 By Investing.com - Investing.com India
Phio Pharmaceuticals Corp (PHIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):